Federated Hermes’s Esperion Therapeutics ESPR Stock Holding History

Federated Hermes’s Portfolio ESPR Stock Details ESPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$87.6K	Buy	+27,706	New	+$77.5K	﹤0.01%	1635
2026 Q1	–	Sell	-1,716	Closed	-$6.35K	–	2091
2025 Q4	$6.35K	Buy	+1,716	New	+$5.54K	﹤0.01%	1875
2020 Q2	–	Sell	-12,900	Closed	-$407K	–	2274
2020 Q1	$407K	Buy	12,900 +12,423	+2,604%	+$656K	﹤0.01%	1435
2019 Q4	$28K	Sell	477 -1,412	-75%	-$63.5K	﹤0.01%	1799
2019 Q3	$69K	Buy	1,889 +725	+62%	+$28.7K	﹤0.01%	1693
2019 Q2	$54K	Buy	+1,164	New	+$54.7K	﹤0.01%	1664
2017 Q2	–	Sell	-10	Closed	-$1K	–	2143
2017 Q1	$1K	Sell	10 -114	-92%	-$2.61K	﹤0.01%	2063
2016 Q4	$2K	Sell	124 -29,731	-100%	-$354K	﹤0.01%	2014
2016 Q3	$413K	Sell	29,855 -5,364	-15%	-$60.8K	﹤0.01%	1334
2016 Q2	$348K	Buy	+35,219	New	+$584K	﹤0.01%	1369
2015 Q4	–	Sell	-12,000	Closed	-$283K	–	2104
2015 Q3	$283K	Buy	12,000 +6,000	+100%	+$377K	﹤0.01%	1429
2015 Q2	$491K	Hold	6,000	–	–	﹤0.01%	1336
2015 Q1	$556K	Buy	+6,000	New	+$387K	﹤0.01%	1337

Other funds holding ESPR

GCL

Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return

OBAM

ODDO BHF Asset Management Paris, France $2.16B AUM 43.32% 1-Year Est. Return

Federated Hermes's ESPR Position: Q2 2026 in Review

Federated Hermes opened a new position in Esperion Therapeutics (ESPR) in Q2 2026: 27,706 shares worth $87.6K. The stake represents ﹤0.01% of the portfolio and ranks #1635 among its holdings. This is a return to the name: Federated Hermes previously reported a position in ESPR as recently as Q4 2025.

Federated Hermes first reported a position in ESPR in Q1 2015 and has held it in 13 quarters since. The position peaked at $556K in Q1 2015. 191 funds tracked by Wall St. Rank hold ESPR as of Q2 2026.

Federated Hermes held 27,706 shares of Esperion Therapeutics worth $87.6K as of Q2 2026.
Esperion Therapeutics was a new Federated Hermes position in Q2 2026.
Esperion Therapeutics made up ﹤0.01% of Federated Hermes's portfolio in Q2 2026, its #1635 holding.
Federated Hermes first reported a position in Esperion Therapeutics in Q1 2015 and has held it in 13 quarters since.
Federated Hermes's Esperion Therapeutics position peaked at $556K in Q1 2015.
191 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2026.

Based on Federated Hermes's 13F filing for Q2 2026, filed 12 Aug 2026.